News

CG100 is a potentially transformative biologic drug that consists of a recombinant human club cell 10kD protein (rhCC10), a secretory protein. rhCC10 is believed to play a major

Alisertib is an oral, selective, inhibitor of Aurora A kinase being investigated by Takeda to treat small cell lung cancer. The decision to discontinue follows the results of

Under the deal, BioQuiddity will secure the requisite regulatory approvals and supplying the unit-dose infusion systems, while Sandoz is responsible to market and commercialize BioQuiddity’s ropivacaine and propofol

The company said that the ilast family of products is scientifically formulated to contain high concentrations of Hyaluronic acid. Available in two formulas, the ilast product offering for

Upon commercialization, ANI will pay Teva up to $5 million at a rate of 5% of the consideration received by ANI as a result of commercial sale of

LCS Group’s exclusive license is part of a unique strategic collaboration with the intellectual property’s owner, Lucerne Biosciences, with further details of the collaboration soon to be announced.

This is one of the largest such screens of its type to date and will drive understanding of the biological mechanisms underlying these conditions and their complications. The

Discovered by BioCryst, BCX7353 is a novel, selective inhibitor of plasma kallikrein in development for prevention of attacks in patients with hereditary angioedema (HAE). BioCryst has successfully completed

Italy is the 23rd country to authorize CEL-SCI’s Phase 3 trial for patient enrollment. Having surpassed its originally planned milestone of receiving authorization to conduct the Phase 3